603882 金域医学
午间休市 09-08 11:29:42
资讯
新帖
简况
金域医学新注册《区域检验质控系统V1.0》等2个项目的软件著作权
证券之星 · 02:15
金域医学新注册《区域检验质控系统V1.0》等2个项目的软件著作权
每周股票复盘：金域医学（603882）股东拟减持不超1%股份
证券之星 · 09-06 02:25
每周股票复盘：金域医学（603882）股东拟减持不超1%股份
金域医学新注册《金域学术资源运营看板系统APPV1.0》项目的软件著作权
证券之星 · 09-05
金域医学新注册《金域学术资源运营看板系统APPV1.0》项目的软件著作权
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》
证券之星 · 09-03
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》
证券之星 · 09-02
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》
金域医学(603882.SH)：国创开元拟减持不超1%股份
智通财经 · 09-01
金域医学(603882.SH)：国创开元拟减持不超1%股份
国金证券：给予金域医学买入评级
证券之星 · 08-26
国金证券：给予金域医学买入评级
金域医学（603882）2026年中报简析：净利润同比增长324.27%，盈利能力上升
证券之星 · 08-26
金域医学（603882）2026年中报简析：净利润同比增长324.27%，盈利能力上升
金域医学（603882）披露2026年半年度报告，8月25日股价下跌1.45%
证券之星 · 08-25
金域医学（603882）披露2026年半年度报告，8月25日股价下跌1.45%
金域医学(603882)6月30日股东户数3.97万户，较上期减少7.89%
证券之星 · 08-25
金域医学(603882)6月30日股东户数3.97万户，较上期减少7.89%
金域医学2026年半年报：降本增效显效，业绩实现扭亏为盈
蓝鲸财经 · 08-25
金域医学2026年半年报：降本增效显效，业绩实现扭亏为盈
图解金域医学中报：第二季度单季净利润同比增长358.50%
证券之星 · 08-25
图解金域医学中报：第二季度单季净利润同比增长358.50%
金域医学(603882.SH)发布半年度业绩，归母净利润1.9亿元，同比扭亏为盈
智通财经 · 08-25
金域医学(603882.SH)发布半年度业绩，归母净利润1.9亿元，同比扭亏为盈
金域医学新注册《方法学比对与正确度分析系统V1.1.2》项目的软件著作权
证券之星 · 08-14
金域医学新注册《方法学比对与正确度分析系统V1.1.2》项目的软件著作权
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票与股票期权激励计划首次授予激励对象名单（首次授予日）的核查意见》
证券之星 · 08-10
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票与股票期权激励计划首次授予激励对象名单（首次授予日）的核查意见》
每周股票复盘：金域医学（603882）推210万限制性股票激励
证券之星 · 08-09
每周股票复盘：金域医学（603882）推210万限制性股票激励
金域医学（603882）披露关于向激励对象首次授予限制性股票与股票期权的公告，8月7日股价上涨3.35%
证券之星 · 08-07
金域医学（603882）披露关于向激励对象首次授予限制性股票与股票期权的公告，8月7日股价上涨3.35%
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司关于以集中竞价交易方式回购公司股份的进展公告》
证券之星 · 08-05
股市必读：金域医学新发布《广州金域医学检验集团股份有限公司关于以集中竞价交易方式回购公司股份的进展公告》
金域医学（603882）披露以集中竞价交易方式回购公司股份的进展公告，8月3日股价下跌0.9%
证券之星 · 08-03
金域医学（603882）披露以集中竞价交易方式回购公司股份的进展公告，8月3日股价下跌0.9%
金域医学：依托30PB高质量医检数据资源形成核心数据服务差异化竞争优势
证券之星 · 08-03
金域医学：依托30PB高质量医检数据资源形成核心数据服务差异化竞争优势
加载更多
公司概况
公司名称：
广州金域医学检验集团股份有限公司
所属行业：
卫生
上市日期：
2017-09-08
主营业务：
广州金域医学检验集团股份有限公司的主营业务是第三方医学检验及病理诊断业务。公司的主要产品是医学诊断服务、销售诊断产品、健康体检业务、冷链物流服务。公司成功入选国家工业和信息化部公布的第七批产业技术基础公共服务平台名单，成为本次获批单位中唯一一家第三方医检机构，标志着公司的综合实力获得国家权威认可。
发行价格：
6.93
{"stockData":{"symbol":"603882","market":"SH","secType":"STK","nameCN":"金域医学","latestPrice":26.08,"timestamp":1788838182000,"preClose":26.37,"halted":0,"volume":2704800,"delay":0,"changeRate":-0.011,"floatShares":459999999,"shares":463000000,"eps":0.2197,"marketStatus":"午间休市","change":-0.29,"latestTime":"09-08 11:29:42","open":26.44,"high":26.46,"low":26.04,"amount":70778400,"amplitude":0.0159,"askPrice":26.1,"askSize":5,"bidPrice":26.08,"bidSize":5,"shortable":0,"etf":0,"ttmEps":0.2197,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788843600000},"marketStatusCode":3,"adr":0,"adjPreClose":26.37,"symbolType":"stock","openAndCloseTimeList":[[1788831000000,1788838200000],[1788843600000,1788850800000]],"highLimit":29.01,"lowLimit":23.73,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":463258275,"isCdr":false,"pbRate":1.93,"roa":"--","peRate":118.707328,"roe":"2.92%","epsLYR":-0.37,"committee":0.731118,"marketValue":12082000000,"turnoverRate":0.0059,"status":1,"floatMarketCap":12000000000},"requestUrl":"/m/hq/s/603882","defaultTab":"news","newsList":[{"id":"2665944310","title":"金域医学新注册《区域检验质控系统V1.0》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2665944310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665944310?lang=zh_cn&edition=full","pubTime":"2026-09-08 02:15","pubTimestamp":1788804916,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金域医学（603882）新注册了2个项目的软件著作权，包括《区域检验质控系统V1.0》、《金域区域检验数据平台移动端V1.0.0》等。今年以来金域医学新注册软件著作权40个，较去年同期减少了42.86%。结合公司2026年中报财务数据，今年上半年公司在研发方面投入了1.57亿元，同比减2.3%。通过天眼查大数据分析，广州金域医学检验集团股份有限公司共对外投资了59家企业，参与招投标项目30次；财产线索方面有商标信息767条，专利信息226条，著作权信息199条；此外企业还拥有行政许可62个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800000682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","159180","BK0236","BK0042","SG9999001069.SGD","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665652983","title":"每周股票复盘：金域医学（603882）股东拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2665652983","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665652983?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:25","pubTimestamp":1788632711,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，金域医学报收于26.7元，较上周的27.42元下跌2.63%。因基金存续期届满，国创开元拟通过集中竞价方式减持不超过4,632,582股，占公司总股本的1.00%。截至2026年8月31日，已累计回购713.38万股，占总股本1.54%，支付金额18,811.76万元，回购最高价30.59元/股，最低价23.36元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","BK0042","603882","BK0284","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665565403","title":"金域医学新注册《金域学术资源运营看板系统APPV1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2665565403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665565403?lang=zh_cn&edition=full","pubTime":"2026-09-05 02:20","pubTimestamp":1788546026,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金域医学（603882）新注册了《金域学术资源运营看板系统APPV1.0》项目的软件著作权。今年以来金域医学新注册软件著作权38个，较去年同期减少了45.71%。结合公司2026年中报财务数据，今年上半年公司在研发方面投入了1.57亿元，同比减2.3%。通过天眼查大数据分析，广州金域医学检验集团股份有限公司共对外投资了59家企业，参与招投标项目30次；财产线索方面有商标信息767条，专利信息226条，著作权信息199条；此外企业还拥有行政许可62个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090500000216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0284","BK0042","603882","159180","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664453748","title":"股市必读：金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664453748","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664453748?lang=zh_cn&edition=full","pubTime":"2026-09-03 01:53","pubTimestamp":1788371592,"startTime":"0","endTime":"0","summary":"公司公告汇总广州金域医学检验集团股份有限公司股东国创开元股权投资基金减持股份计划公告广州金域医学检验集团股份有限公司股东国创开元股权投资基金持有公司30,880,905股，占总股本的6.67%，股份来源为公司首次公开发行前取得。因基金存续期届满，国创开元拟通过集中竞价方式减持不超过4,632,582股，占公司总股本的1.00%。截至2026年8月31日，已累计回购713.38万股，占总股本1.54%，支付金额18,811.76万元，回购最高价30.59元/股，最低价23.36元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","SG9999001069.SGD","BK0042","BK0284","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664863633","title":"股市必读：金域医学新发布《广州金域医学检验集团股份有限公司股东国创开元股权投资基金(有限合伙)减持股份计划公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664863633","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664863633?lang=zh_cn&edition=full","pubTime":"2026-09-02 01:28","pubTimestamp":1788283691,"startTime":"0","endTime":"0","summary":"公司公告汇总：截至2026年8月31日，金域医学已回购713.38万股，支付金额18,811.76万元，占总股本1.54%。公司公告汇总广州金域医学检验集团股份有限公司股东国创开元股权投资基金减持股份计划公告广州金域医学检验集团股份有限公司股东国创开元股权投资基金持有公司30,880,905股，占总股本的6.67%，股份来源为公司首次公开发行前取得。因基金存续期届满，国创开元拟通过集中竞价方式减持不超过4,632,582股，占公司总股本的1.00%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200001885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0042","BK0236","603882","BK0284"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664830027","title":"金域医学(603882.SH)：国创开元拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2664830027","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664830027?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:06","pubTimestamp":1788257193,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金域医学(603882.SH)发布公告，因基金存续期届满，股东国创开元拟通过集中竞价方式减持所持有的公司股份不超过463.26万股，占公司总股本的1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603882","BK0284","BK0042","BK0236","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662765559","title":"国金证券：给予金域医学买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662765559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662765559?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:43","pubTimestamp":1787705002,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕近期对金域医学进行研究并发布了研究报告《盈利能力修复，医数融合构筑新增长》，给予金域医学买入评级。 金域医学 2026年8月24日，公司发布2026年半年度报告。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级5家，增持评级2家；过去90天内机构目标均价为36.62。本文数据来源于国金证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600014986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662570877","title":"金域医学（603882）2026年中报简析：净利润同比增长324.27%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662570877","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662570877?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:13","pubTimestamp":1787696001,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期金域医学发布2026年中报。截至本报告期末，公司营业总收入28.84亿元，同比下降3.76%，归母净利润1.9亿元，同比上升324.27%。本报告期金域医学盈利能力上升，毛利率同比增幅8.19%，净利率同比增幅327%。持有金域医学最多的基金为大成景恒混合A，目前规模为3.88亿元，最新净值3.5057，较上一交易日上涨1.77%，近一年上涨0.72%。本文数据来源于金域医学2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600009457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662973655","title":"金域医学（603882）披露2026年半年度报告，8月25日股价下跌1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662973655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662973655?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:46","pubTimestamp":1787654814,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，金域医学报收于29.3元，较前一交易日下跌1.45%，最新总市值为135.73亿元。公司于近日披露《广州金域医学检验集团股份有限公司2026年半年度报告》。公告显示，截至报告期末，公司总资产为9,138,563,699.60元，归属于上市公司股东的净资产为6,314,304,429.52元，较上年度末分别减少4.85%和6.17%。经营活动产生的现金流量净额为242,620,468.80元，同比减少30.77%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500039702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","603882","BK0284","BK0042","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662738310","title":"金域医学(603882)6月30日股东户数3.97万户，较上期减少7.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662738310","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662738310?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:38","pubTimestamp":1787650734,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金域医学披露，截至2026年6月30日公司股东户数为3.97万户，较3月31日减少3401.0户，减幅为7.89%。在医疗服务行业个股中，金域医学股东户数低于行业平均水平，截至6月30日，医疗服务行业平均股东户数为4.77万户。从股价来看，2026年3月31日至2026年6月30日，金域医学区间跌幅为14.39%，在此期间股东户数减少3401.0户，减幅为7.89%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500036682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","BK0236","BK0284","SG9999001069.SGD","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662783837","title":"金域医学2026年半年报：降本增效显效，业绩实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2662783837","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662783837?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:37","pubTimestamp":1787629056,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月25日讯，8月24日，金域医学 公布2026年中报，公司依托第三方医学检验与病理诊断核心业务，通过持续推进降本增效及数智化转型，有效消化前期阶段性不利因素，报告期业绩实现扭亏为盈；同时，毛利率显著提升，经营韧性增强，核心业务发展逐步企稳。财报数据显示，报告期公司实现营业收入28.84亿元，同比下降3.76%；归母净利润1.90亿元，同比扭亏为盈；扣非净利润2.03亿元，同比增长307.38%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787624576896228463","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0284","603882","BK0042","BK0236","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662220345","title":"图解金域医学中报：第二季度单季净利润同比增长358.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662220345","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662220345?lang=zh_cn&edition=full","pubTime":"2026-08-25 02:40","pubTimestamp":1787596802,"startTime":"0","endTime":"0","summary":"证券之星消息，金域医学2026年中报显示，上半年度公司主营收入28.84亿元，同比下降3.76%；归母净利润1.9亿元，同比上升324.27%；扣非净利润2.03亿元，同比上升307.38%；其中2026年第二季度，公司单季度主营收入15.33亿元，同比上升0.19%；单季度归母净利润1.47亿元，同比上升358.5%；单季度扣非净利润1.51亿元，同比上升355.34%；负债率29.42%，投资收益347.78万元，财务费用193.05万元，毛利率36.71%。财报数据概要请见下图:本文数据来源于金域医学2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500005559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662221270","title":"金域医学(603882.SH)发布半年度业绩，归母净利润1.9亿元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2662221270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662221270?lang=zh_cn&edition=full","pubTime":"2026-08-25 00:33","pubTimestamp":1787589180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金域医学 披露2026年半年度报告，报告期公司实现营业收入28.84亿元，同比下降3.76%;归属于上市公司股东的净利润1.9亿元，同比扭亏为盈;归属于上市公司股东的扣除非经常性损益的净利润2.03亿元，同比扭亏为盈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"金域医学(603882.SH)发布半年度业绩，归母净利润1.9亿元，同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659161440","title":"金域医学新注册《方法学比对与正确度分析系统V1.1.2》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2659161440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659161440?lang=zh_cn&edition=full","pubTime":"2026-08-14 02:23","pubTimestamp":1786645395,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金域医学（603882）新注册了《方法学比对与正确度分析系统V1.1.2》项目的软件著作权。今年以来金域医学新注册软件著作权37个，较去年同期减少了41.27%。结合公司2025年年报财务数据，2025年公司在研发方面投入了3.41亿元，同比减14.78%。通过天眼查大数据分析，广州金域医学检验集团股份有限公司共对外投资了59家企业，参与招投标项目29次；财产线索方面有商标信息766条，专利信息223条，著作权信息198条；此外企业还拥有行政许可62个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0042","BK0236","603882","BK0284","159180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658047670","title":"股市必读：金域医学新发布《广州金域医学检验集团股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票与股票期权激励计划首次授予激励对象名单（首次授予日）的核查意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658047670","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658047670?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:02","pubTimestamp":1786298537,"startTime":"0","endTime":"0","summary":"广州金域医学检验集团股份有限公司2026年限制性股票与股票期权激励计划首次授予激励对象名单金域医学公布2026年限制性股票与股票期权激励计划首次授予激励对象名单：李慧源获授限制性股票16.5606万股，马骥获授股票期权27.6008万份；40名中层管理人员合计获授限制性股票176.8788万股、股票期权294.7984万份；预留权益140.0000万股，占授予权益总数20.00%；本次授予权益总数700.0000万份，占公司总股本1.52%；激励对象不包括独立董事及持股5%以上股东及其关联人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","603882","BK0042","BK0284","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658467538","title":"每周股票复盘：金域医学（603882）推210万限制性股票激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2658467538","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658467538?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:28","pubTimestamp":1786213693,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，金域医学报收于28.97元，较上周的27.76元上涨4.36%。本周，金域医学8月7日盘中最高价报29.36元。本周关注点公司公告汇总：金域医学向42名激励对象授予210万股限制性股票，授予价格12.78元/股。截至2026年7月31日，已累计回购676.88万股，占总股本1.46%，支付金额17,758.25万元，回购价格区间为23.36元/股至28.79元/股。本次授予权益总数合计700.0000万份，占公司总股本的1.52%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0236","BK0284","BK0042","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657264411","title":"金域医学（603882）披露关于向激励对象首次授予限制性股票与股票期权的公告，8月7日股价上涨3.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657264411","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657264411?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:25","pubTimestamp":1786112709,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，金域医学报收于28.97元，较前一交易日上涨3.35%，最新总市值为134.21亿元。近日，广州金域医学检验集团股份有限公司发布《关于向激励对象首次授予限制性股票与股票期权的公告》。公告显示，公司于2026年8月7日召开第四届董事会第十四次会议，确定向42名激励对象首次授予210万股限制性股票和350万份股票期权，授予日为2026年8月7日，限制性股票授予价格为12.78元/股，股票期权行权价格为25.55元/份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0236","BK0284","BK0042","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563449","title":"股市必读：金域医学新发布《广州金域医学检验集团股份有限公司关于以集中竞价交易方式回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563449","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657563449?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:06","pubTimestamp":1785866775,"startTime":"0","endTime":"0","summary":"公司公告汇总：截至2026年7月31日，金域医学已累计回购676.88万股，支付金额17,758.25万元，回购进度达承诺下限的118.39%。公司公告汇总广州金域医学检验集团股份有限公司关于以集中竞价交易方式回购公司股份的进展公告2026年4月10日，公司董事会审议通过回购股份方案，拟以自有资金和自筹资金通过集中竞价交易方式回购股份，用于股权激励，回购金额不低于15,000万元不超过20,000万元，价格不超35.00元/股，期限为6个月。2026年7月单月回购15.5万股，支付415.88万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999001069.SGD","BK0236","BK0042","BK0284","603882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656854377","title":"金域医学（603882）披露以集中竞价交易方式回购公司股份的进展公告，8月3日股价下跌0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656854377","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656854377?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:17","pubTimestamp":1785766652,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，金域医学报收于27.51元，较前一交易日下跌0.9%，最新总市值为127.44亿元。该股当日开盘27.76元，最高28.28元，最低27.42元，成交额达1.59亿元，换手率为1.25%。近日，广州金域医学检验集团股份有限公司发布《关于以集中竞价交易方式回购公司股份的进展公告》。2026年7月单月回购15.5万股，支付415.88万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300037121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0284","603882","BK0042","BK0236","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656067326","title":"金域医学：依托30PB高质量医检数据资源形成核心数据服务差异化竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2656067326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656067326?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:33","pubTimestamp":1785742393,"startTime":"0","endTime":"0","summary":"请问公司是否计划依托域见医言大模型，为创新药企提供靶向药研发数据集、AI辅助临床分层、耐药机制分析等AI制药配套服务？后续有无向AI创新药研发服务商延伸的规划？公司依托30PB的高质量医检数据资源、数据治理能力、数据平台支撑能力，形成了核心数据服务层面的差异化竞争优势。公司将持续关注该领域的发展机遇，并依托数据资源和AI能力，积极探索相关的服务模式。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300014424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603882","BK0236","BK0284","BK0042","SG9999001069.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788839703782,"stockEarnings":[{"period":"1week","weight":-0.0369},{"period":"1month","weight":-0.0897},{"period":"3month","weight":0.072},{"period":"6month","weight":-0.078},{"period":"1year","weight":-0.1215},{"period":"ytd","weight":-0.044}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.0193},{"period":"6month","weight":-0.0486},{"period":"1year","weight":0.0315},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广州金域医学检验集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"39725人(较上一季度减少7.89%)","perCapita":"11582股","listingDate":"2017-09-08","address":"广东省广州市海珠区国际生物岛螺旋三路10号","registeredCapital":"46325万元","survey":" 广州金域医学检验集团股份有限公司的主营业务是第三方医学检验及病理诊断业务。公司的主要产品是医学诊断服务、销售诊断产品、健康体检业务、冷链物流服务。公司成功入选国家工业和信息化部公布的第七批产业技术基础公共服务平台名单，成为本次获批单位中唯一一家第三方医检机构，标志着公司的综合实力获得国家权威认可。","listedPrice":6.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金域医学(603882)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金域医学(603882)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金域医学,603882,金域医学股票,金域医学股票老虎,金域医学股票老虎国际,金域医学行情,金域医学股票行情,金域医学股价,金域医学股市,金域医学股票价格,金域医学股票交易,金域医学股票购买,金域医学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金域医学(603882)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金域医学(603882)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}